Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase.

Published byΚασσιέπεια Σωστράτη Αγγελόπουλος Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase."— Presentation transcript:

1 Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase of lipoprotein fraction (LPF) and EDV (r = 0.35, P = 0.036), (C) and diene conjugates (DC) and EDV (r = −... Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase of lipoprotein fraction (LPF) and EDV (r = 0.35, P = 0.036), (C) and diene conjugates (DC) and EDV (r = −0.53, P = ). Margus Annuk et al. JASN 2001;12: ©2001 by American Society of Nephrology

Download ppt "Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase."

Similar presentations

Phase Difference = 0.00. Phase Difference = 0.05.

Phase Difference = Phase Difference = 0.05.
Patient disposition for the double-blind study period.

Patient disposition for the double-blind study period.
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
Key amino acid positions identified by association analysis are highlighted in three-dimensional ribbon models for the HLA-DR, HLA-DQ, HLA-A and HLA-DP.

Key amino acid positions identified by association analysis are highlighted in three-dimensional ribbon models for the HLA-DR, HLA-DQ, HLA-A and HLA-DP.
Five independent associations were identified after stepwise association analysis within the MHC region at the discovery stage. Five independent associations.

Five independent associations were identified after stepwise association analysis within the MHC region at the discovery stage. Five independent associations.
Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.

Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.
Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.

Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.
Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.

Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.
Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];

Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];
Missense mutations in TNXB as a cause of VUR

Missense mutations in TNXB as a cause of VUR
Studies reporting the incident rate for ischemic steal syndrome per 1000 patient days. Studies reporting the incident rate for ischemic steal syndrome.

Studies reporting the incident rate for ischemic steal syndrome per 1000 patient days. Studies reporting the incident rate for ischemic steal syndrome.
Figure 6. Representative micrographs showing macrophages and nitrotyrosine in atherosclerotic plaques in aortic root cross-sections from apo-E −/− mice.

Figure 6. Representative micrographs showing macrophages and nitrotyrosine in atherosclerotic plaques in aortic root cross-sections from apo-E −/− mice.
Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.

Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.
Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF
Pedigrees of the families of patients 1 and 2 show that the clinical phenotype co-segregates with compound heterozygous CLDN10 variants. Pedigrees of the.

Pedigrees of the families of patients 1 and 2 show that the clinical phenotype co-segregates with compound heterozygous CLDN10 variants. Pedigrees of the.
Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.

Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.
HPLC tracings of resveratrol (RV) and its major sulfate conjugates M4/M5 in the plasma from three subjects. HPLC tracings of resveratrol (RV) and its major.

HPLC tracings of resveratrol (RV) and its major sulfate conjugates M4/M5 in the plasma from three subjects. HPLC tracings of resveratrol (RV) and its major.
Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.

Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Similar presentations

Ads by Google